Gastrointestinal Cancer

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses combinations with targeted agents in colorectal cancer.

Aparna R. Parikh, MD, medical oncologist, Massachusetts General Hospital, discusses the applicability of liquid biopsies in gastrointestinal cancers.

David J. Pinato, MD, PhD, NIHR Academic Clinical Lecturer in Medical Oncology, resident, Royal Brompton Hospital and Imperial College London, discusses pheochromocytomas and paragangliomas.

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the next steps for napabucasin with FOLFIRI and bevacizumab (Avastin) as treatment for patients with colorectal cancer.

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the impact of the recent progress in the second-line treatment setting for hepatocellular carcinoma.

Brandon Huffman, MD, resident physician, internal medicine, Mayo Clinic, discusses the survival analysis from a study of patients with solid pseudopapillary tumors of the pancreas.

Dominik P. Modest, MD, University of Munich, discusses an evaluation of resection in patients with metastatic colorectal cancer.

Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CheckMate-032 study in gastric and gastroesophageal junction cancer.

Ziv-aflibercept (Zaltrap) prolonged overall survival compared to placebo across subgroups of patients with metastatic colorectal cancer with wild-type and mutated RAS, KRAS, and BRAF genes.

While expected improvements in survival did not emerge with SIRT plus chemotherapy, an unanticipated benefit was observed with SIRT in patients with metastatic colorectal cancer.

Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses a carcinoembryonic antigen T-cell bispecific antibody.

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses napabucasin with FOLFIRI and bevacizumab (Avastin) in colorectal cancer.

Recent developments in the treatment of metastatic pancreatic cancer have modestly improved outcomes, but reducing morbidities associated with current therapies and developing novel therapeutics will be essential for achieving durable responses and long-term survival.

In a central evaluation for surgical treatment options in the FIRE-3 study results, investigators set out to determine the number of patients with metastatic colorectal cancer who had resectable disease during systemic first-line therapy.

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses immunotherapy in gastrointestinal cancers.

Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/ Oncology, University Hospital Halle, discusses the results of the CHARTA study in colorectal cancer.

The novel stemness inhibitor napabucasin in combination with different standard chemotherapy backbones demonstrated promising activity in metastatic pancreatic adenocarcinoma and metastatic colorectal cancer.

CEA-TCB showed a favorable safety profile and promising efficacy in patients with heavily-pretreated microsatellite stable metastatic colorectal cancer, with enhanced efficacy when combined with atezolizumab.

Aparna Parikh, MD, discusses the potential impact of liquid biopsies in overcoming resistance to targeted therapies in gastrointestinal cancer.

Patients with unresectable HCC continue to show statistically significant improvement in overall survival with second-line regorafenib (Stivarga) treatment.

Durable responses and improved long-term survival were demonstrated with nivolumab (Opdivo) that were not altered by the age of patients with advanced hepatocellular carcinoma across all age groups of patients participating in the CheckMate 040 trial.

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses napabucasin with gemcitabine and nab-paclitaxel in pancreatic adenocarcinoma.

Aparna R. Parikh, MD, medical oncologist, Massachusetts General Hospital, discusses liquid biopsies in gastrointestinal cancers.

The FDA has approved panitumumab in combination with FOLFOX as a frontline treatment for patients with RAS wild-type metastatic colorectal cancer.

Luis A. Diaz, MD, discusses KEYNOTE-177 and the implications of the FDA approval of pembrolizumab for patients with MSI-H or dMMR CRC or other solid tumors.